• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—May 21

    Iterative Scopes Expands its Senior Leadership Team

    Viz.ai Raises $100 Million in Series D Funding

    FDA Clears Arterys' AI Mapping and Quantification Tools

    Prometheus Group Sued Over Reused Catheters and Rectal Sensors
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Injecting Neurostimulators into Blood Vessels (We Swear, It’s Not Sci-Fi)

    Understanding the Costs of Care in the OR

    Sick of Being Sick: Pandemic Fatigue Flares at AAOS

    Managing Critical Healthcare Supply Chains in Turbulent Times

    To Drive Value, Human Capital Leaders Turn to Outsourced Solutions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Xact Wire EDM Corp.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical

    BMP Medical

    Trademark Plastics Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing in Dental Prosthodontics, Orthodontics, and Surgery

    What New Tech Can Improve Your Medical Manufacturing Plant?

    Why Medical Device Firms Must Navigate the Muddy Waters of ESG Requirements

    Medical Device Servicing vs. Remanufacturing

    Digital Marketplaces for Medical Equipment Come of Age
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Xact Wire EDM Corp.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical

    BMP Medical

    Trademark Plastics Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Late-Breaking Analyses from Landmark COAPT Trial Show Benefits of Abbott's MitraClip

    Treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy.

    Late-Breaking Analyses from Landmark COAPT Trial Show Benefits of Abbott
    Data from a sub-analysis of imaging data provides further clarity regarding which patients benefit most from treatment with MitraClip. Image courtesy of Abbott.
    Related CONTENT
    • Breakthrough Device Designation Granted for New Neuromodulation Platform
    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    • Improved Outcomes Proven With Insulet’s Omnipod 5 System
    • Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe
    • Vertigo Treatment Receives FDA Breakthrough Device Designation
    Abbott Laboratories03.19.19
    Abbott announced positive late-breaking data from two separate analyses of the COAPT Trial showing additional key benefits from treatment with MitraClip for heart failure patients with clinically significant secondary (or functional) mitral regurgitation (MR), or leaky heart valve. Both data sets were presented at the American College of Cardiology's (ACC) 68th Annual Scientific Session. On Thursday, the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for MitraClip to treat secondary mitral regurgitation based on the COAPT Trial data.
     
    During the late-breaking session at ACC, MitraClip was shown to be superior to guideline-directed medical therapy in providing quality-of-life improvements for select patients with significant secondary MR resulting from advanced heart failure. These data were simultaneously published in the Journal of the American College of Cardiology. A second sub-analysis measured baseline characteristics of heart failure patients prior to enrollment in the COAPT Trial and indicated that all subgroups of patients enrolled in the trial benefited from MitraClip therapy in the long-term.
     
    "Following the groundbreaking data from the COAPT Trial presented last September, these analyses further confirm that treatment with MitraClip provides great benefit for select patients with advanced heart failure," said Gregg W. Stone, M.D., co-principal investigator of the COAPT Trial, director of cardiovascular research and education at NewYork-Presbyterian/Columbia University Irving Medical Center and professor of medicine at Columbia University Vagelos College of Physicians and Surgeons. "In patients who remained symptomatic with moderate-to-severe or severe MR, despite all the best medical treatments, MitraClip prolonged their survival and markedly reduced the need for hospitalizations while improving their daily lives—despite advanced age and comorbidities."
     
    People with heart failure may develop secondary MR when the left chamber of the heart becomes enlarged, preventing the mitral leaflets from closing and allowing blood to flow backwards through the heart.1 Significant secondary MR is difficult to manage, is associated with a poor prognosis,2 and can lead to reduced quality of life, recurrent hospitalizations and decreased survival.3,4 Most heart failure patients with clinically significant secondary MR are treated with medication only and have few treatment options.5 However, based on the recent approval, these patients can now benefit from treatment with MitraClip for their secondary MR.
     
    MitraClip is a small, clip-based device that repairs MR without the need for open-heart surgery. It is delivered to the heart through a small incision in the leg. The device works by clipping together a portion of the leaflets of the mitral valve to reduce the backflow of blood, which allows the heart to pump blood more efficiently. Approximately one in 10 adults age 75 and older in the U.S., or four million Americans, suffer from MR.6,7,8 It's estimated that two to three times as many patients may now benefit from MitraClip treatment for secondary MR as a result of underlying heart failure than those treated for the primary form of the disease commonly associated with the deterioration of the valve structure.9
     
    "These additional analyses from the landmark COAPT Trial point to the advantages of MitraClip treatment for patients with severe MR who are not benefitting from medical therapy," said Michael Dale, vice president of Abbott's structural heart business. "The data underscore our recent approval to help these people who desperately need treatment, giving them the ability to do the things many of us take for granted: things like breathing normally, lying down to sleep and walking to the mailbox."
     
    Quality-of-Life Data
    The COAPT quality-of-life analysis showed that, at 24 months, patients with heart failure and secondary MR receiving maximally-tolerated medical therapy and treated with MitraClip demonstrated substantial and sustained health status improvement (≥10 points) compared with medical therapy (36.4 percent vs. 16.6 percent; p<0.001). While quality-of-life was unchanged over time in the medical therapy group, patients treated with MitraClip demonstrated substantial improvement in the KCCQ-OS score, a self-assessment of social abilities, symptoms, and quality-of-life, as soon as one month after the procedure (mean between-group difference 15.9 points, p<0.001), a difference which persisted through 24 months. The quality-of-life benefit of MitraClip was consistent across all subgroups through 24 months.
     
    The COAPT trial randomized patients with ASE (American Society of Echocardiography) classification 3-4+ (moderate-to-severe to severe) secondary MR to treatment with MitraClip plus medical therapy (n=302) or medical therapy alone (n=312). At baseline, patients in both groups had substantially impaired quality-of-life due to their advanced heart failure. Quality-of-life was assessed at baseline and at one, six, 12 and 24 months.
     
    Echocardiographic Sub-Analysis of COAPT Trial Data
    In the COAPT imaging sub-analysis, patients were screened to assess the severity of secondary MR prior to enrollment in the trial, and to determine which patient characteristics best predict favorable long-term outcomes with MitraClip. A specific imaging protocol was developed and employed to select patients with severe MR who might benefit from the MitraClip device. A substantial reduction in death and heart failure hospitalizations was seen in all imaging subgroups regardless of patients' baseline characteristics.
     
    In the sub-analysis, there were 614 patients with heart failure and ASE class 3+ or 4+ secondary MR enrolled and randomized 1:1 to MitraClip and medical therapy or medical therapy alone based on an integrated assessment of the severity of regurgitation using multiple measures and parameters. Follow-up cardiac imaging was obtained at discharge, one, six, 12, 18 and 24 months, and yearly through five years. Clinical follow-up is currently complete through one year in all patients and through two years in many of the patients.
     
    About the COAPT Trial
    In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) Trial, 614 symptomatic heart failure patients with moderate-to-severe or severe secondary MR were randomized to receive treatment with MitraClip plus guideline-directed medical therapy or guideline-directed medical therapy alone at 78 sites in the U.S. and Canada. Eligible patients had diseased heart muscle, known as dilated cardiomyopathy that reduced the amount of blood pumped from the left ventricle; and moderate-to-severe or severe MR assessed by the American Society of Echocardiography guidelines that remained symptomatic despite maximally-tolerated medical therapy and cardiac resynchronization therapy (if appropriate).10,11 Mean patient age was 72.2 years, and 64 percent were male.
     
    The primary efficacy endpoint in the COAPT Trial was all heart failure hospitalizations through two years, and the primary safety endpoint was freedom from device-related complications at one year compared to a performance goal of 88 percent. Secondary endpoints included all-cause mortality at two years, change in quality-of-life at one year, change in functional capacity (six minute walk distance) at one year, MR severity at one year and left ventricle size at one year. The COAPT Trial met its primary endpoints and all 10 secondary endpoints as presented during the TCT cardiology meeting in Sept. 2018 and published in the New England Journal of Medicine.12
     
    References
    1 Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 2015;65:1231-48.
    2 Dwivedi A, Vainrib A, Saric M. Functional mitral regurgitation in patients with heart failure and depressed ejection fraction. Current Opinion in Cardiology. September 2016 - Volume 31 - Issue 5 - p 483–492.  
    3 Sannino A, Smith II RL, Schiattarrella GG, et al. Survival and cardiovascular outcomes of patients with secondary mitral regurgitation: a meta-analysis of 53 studies. JAMA Cardiology 2017; 2:1130-39.
    4 Goliasch G, Bartko PE, Pavo N, et al. Refining the prognosis impact of functional mitral regurgitation in chronic heart failure. Eur Heart J 2018;39:39-46.
    5 Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63:185-6.
    6 Dziaddzko et al, "Outcome and Undertreatment of Mitral Regurgitation:  a Community Cohort Study", Lancet 2018:  391:960-69.
    7 AHA Heart Disease and Stroke Statistics Update, Circulation 2017.
    8 Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA /guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Caridol. 2017;70:776-803.
    9 Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63:185-6.
    10 Pecini et al EHJ 2011; Asgar et al, JACC 2015;  Nieminen et al, EHJ 2006; Patel et al, Journal of Cardiac Failure 2004.
    11 Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 201;70:252-289.
    12 Stone GW, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018 Dec 13;379(24):2307-2318.
    Related Searches
    • mr
    • patient
    • 2013
    • sleep
    Related Knowledge Center
    • Surgical
    • Cardiovascular
    Suggested For You
    Breakthrough Device Designation Granted for New Neuromodulation Platform Breakthrough Device Designation Granted for New Neuromodulation Platform
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Improved Outcomes Proven With Insulet’s Omnipod 5 System Improved Outcomes Proven With Insulet’s Omnipod 5 System
    Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    FDA Approves TransMedics FDA Approves TransMedics' OCS Heart System for Donor Hearts
    RonovoRx RonovoRx's RenovoCath Earns New FDA 510(k)
    Bright Future Ahead for Renal Denervation Bright Future Ahead for Renal Denervation
    Acutus Medical Receives FDA Clearance for AcQMap 8 Software Upgrades Acutus Medical Receives FDA Clearance for AcQMap 8 Software Upgrades
    FDA Approves ZOLL FDA Approves ZOLL's remedē for Central Sleep Apnea
    Early Catheter Ablation of VT Outperforms Conventional Medical Therapy Early Catheter Ablation of VT Outperforms Conventional Medical Therapy
    Study: Human Oversight ECG Monitors Outperform AI-Dependent Monitoring Study: Human Oversight ECG Monitors Outperform AI-Dependent Monitoring
    Abbott Fined $160M to Resolve Medicare Diabetes Lawsuit Abbott Fined $160M to Resolve Medicare Diabetes Lawsuit
    Non-Profit Group Launches Initiative to Diversify Medtech Workforce Non-Profit Group Launches Initiative to Diversify Medtech Workforce
    BioFourmis BioFourmis' Digital Heart Failure Therapeutic Earns Breakthrough Status

    Related Content

    • Breakthrough Device Designation Granted for New Neuromodulation Platform

      Breakthrough Device Designation Granted for New Neuromodulation Platform

      In a pilot study treating refractory epilepsy with Neuroelectrics’ Starstim platform, patients experienced a 44 percent median reduction in seizure frequency.
      Business Wire 09.22.21

    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Sleeve based on a medical technique called Direct Wire Pacing, which was invented by the company’s founder.
      Electroducer 09.21.21

    • Improved Outcomes Proven With Insulet’s Omnipod 5 System

      Improved Outcomes Proven With Insulet’s Omnipod 5 System

      Studies show the automated insulin delivery system improved HbA1c nearly one percentage point in kids and 0.60 percent in adolescents and adults.
      Business Wire 09.16.21


    • Patient Monitoring
      Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe

      Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe

      Uses 12 LEDs to simultaneously offer 12 blood constituent parameters noninvasively and continuously.
      Business Wire 09.13.21

    • Vertigo Treatment Receives FDA Breakthrough Device Designation

      Vertigo Treatment Receives FDA Breakthrough Device Designation

      The device's developer—Otolith Labs—closes $3.3 million in seed financing.
      Business Wire 09.13.21


      Trending
      • 5 Ways Plastics Revolutionized The Healthcare Industry | Medical Product Outsourcing
      • The Future Of Biomedical Engineering Advancements | Medical Product Outsourcing
      • Accelerating Product Development In The Age Of Digital Innovation | Medical Product Outsourcing
      • Viz.ai Raises $100 Million In Series D Funding | Medical Product Outsourcing
      • Medical Device Trends To Watch For In 2022 And Beyond | Medical Product Outsourcing
      Breaking News
      • MPO's Most-Read Stories This Week—May 21
      • Iterative Scopes Expands its Senior Leadership Team
      • Viz.ai Raises $100 Million in Series D Funding
      • FDA Clears Arterys' AI Mapping and Quantification Tools
      • Prometheus Group Sued Over Reused Catheters and Rectal Sensors
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Cybersecurity Challenges Leave Medical Device Makers Insecure
      • Contract Design for Medtech
      • Diabetes Medical Device Technology Update
      • Medtech Full-Service Outsourcing Q&A 2022

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      What Are You Reading?
      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      P&G Closes HQ Due To Security Threat, Launches New Hair Care Line
      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Kimberly-Clark to Expand Diaper, Wipes Production in Brazil; The Honest Company to Sell Diapers, Wipes at Walmart & More
      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login